Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis has announced that the FDA approved Apidra SoloSTAR, a prefilled disposable pen containing rapid-acting insulin analog Apidra, which is indicated to improve glycemic control in adults and children four years and older with type 1 diabetes or adults with type 2 diabetes.
Subscribe to our email newsletter
The approval of Apidra SoloSTAR follows the approval and launch of Lantus SoloSTAR (insulin glargine (rDNA origin) injection) in 2007. Apidra SoloSTAR is expected to be available in pharmacies in 2009.
Angela Moskow, vice president of metabolism marketing for US at Sanofi-Aventis, said: “Patients with diabetes have to contend with the challenges of carbohydrate counting, regular blood sugar monitoring and careful administration of their insulin. Apidra SoloSTAR represents another innovation introduced by Sanofi-Aventis that offers patients a convenient option for administering their Apidra.”